Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2035-09-30
Target enrollment:
Participant gender:
Summary
Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black
participants compared to the efficacy reported in the historical trials leading to US FDA
approval of the regimen